AirNexis Therapeutics, Inc.
About
A clinical-stage biotechnology startup founded in January 2026, focused on developing and commercializing novel therapeutics for respiratory diseases like chronic obstructive pulmonary disease (COPD). The company's business model involves in-licensing late-stage clinical assets and advancing them through global development outside of Greater China. Its lead program is a dual PDE3/4 inhibitor for COPD maintenance treatment.
Company Values
The company launched with a significant $200 million Series A financing and a clinical-stage asset, AN01, allowing it to bypass early discovery and focus immediately on late-stage global development. This strategy, combined with an experienced leadership team and strong investor backing, positions it to quickly address unmet needs in the large COPD market.